Arterial conduits are increasingly preferred for surgical bypass because of inherent functional properties conferred by arterial endothelial cells, especially nitric oxide production in response to physiologic stimuli. Here we tested whether endothelial progenitor cells (EPCs) can replace arterial endothelial cells and promote patency in tissue-engineered small-diameter blood vessels (4 mm). We isolated EPCs from peripheral blood of sheep, expanded them ex vivo and then seeded them on decellularized porcine iliac vessels. EPC-seeded grafts remained patent for 130 days as a carotid interposition graft in sheep, whereas non-seeded grafts occluded within 15 days. The EPC-explanted grafts exhibited contractile activity and nitric-oxide-mediated vascular relaxation that were similar to native carotid arteries. These results indicate that EPCs can function similarly to arterial endothelial cells and thereby confer longer vascular-graft survival. Due to their unique properties, EPCs might have other general applications for tissue-engineered structures and in treating vascular diseases.
|Original language||English (US)|
|Number of pages||6|
|State||Published - 2001|
Bibliographical noteFunding Information:
Acknowledgments We thank D. Zvagelsky for technical assistance with preparing tissue sections; E. Rhee for providing the arteriograms; Sulzer Carbomedics for providing the vessel bioreactor; K. Gullage and J. Fox for preparation of the figures; and J. Folkman, C. Lowenstein, S. Roth and J. Schneider for critically reading the manuscript. This work was supported by RO1 HL 60490 (J.B.) and RO1 HL 60463 (J.E.M. Jr) from the National Heart, Lung and Blood Institute and the Sarnoff Foundation (S.K.).